Cargando…
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
BACKGROUND: Although the role of immunoglobulin E (IgE) in immunity against helminth parasites is unclear, there is concern that therapeutic antibodies that neutralize IgE (anti-IgE) may be unsafe in subjects at risk of helminth infection. OBJECTIVE: We conducted an exploratory study to investigate...
Autores principales: | Cruz, A A, Lima, F, Sarinho, E, Ayre, G, Martin, C, Fox, H, Cooper, P J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1859973/ https://www.ncbi.nlm.nih.gov/pubmed/17250692 http://dx.doi.org/10.1111/j.1365-2222.2007.02650.x |
Ejemplares similares
-
Omalizumab, an anti-immunoglobulin E antibody: state of the art
por: Incorvaia, Cristoforo, et al.
Publicado: (2014) -
Maternal Geohelminth Infections Are Associated with an Increased Susceptibility to Geohelminth Infection in Children: A Case-Control Study
por: Mehta, Raaj S., et al.
Publicado: (2012) -
Environmental contamination by canine geohelminths
por: Traversa, Donato, et al.
Publicado: (2014) -
Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
por: Menzella, Francesco, et al.
Publicado: (2023) -
Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)